Amendment to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (previously presented): A system for treating a vascular condition, comprising:

a catheter; and

a coated stent operably coupled to the catheter, the coated stent including a plurality of therapeutic coatings disposed on a distal end and a proximal end of the stent and a plurality of timing coatings disposed on the distal and proximal ends of the stent, the timing coatings alternating with the therapeutic coatings, wherein each therapeutic coating comprises a bioerodable polymer and a therapeutic agent and wherein each timing coating comprises a bioerodable polymer, wherein each of the plurality of therapeutic agents is released from the plurality of therapeutic coatings, the therapeutic agents in each of the therapeutic coatings being released exclusively and sequentially upon the erosion of the overlying timing coating without release of the therapeutic agents from other of the therapeutic coatings to inhibit restenosis adjacent to the ends of the stent.

Claim 2 (original): The system of claim 1 wherein the therapeutic agents are selected from a group consisting of an antiproliferative agent, an antineoplastic agent, an antibiotic agent, an anti-inflammatory agent, a free radical scavenger, a protein, and combinations thereof.

Claim 3 (original): The system of claim 1 wherein the therapeutic agents are selected from a group consisting of paclitaxel, dexamethasone, rapamycin, a rapamycin analog, a nonsteroidal anti-inflammatory drug, a steroidal anti-inflammatory drug, a superoxide dismutase mimic, apo A-1 Milano, and combinations thereof.

Claims 4-6 (cancelled)

Claim 7 (previously presented): The system of claim 1 wherein each timing coating prevents release of the therapeutic agent from the therapeutic coating positioned beneath the timing coating until a predetermined time.

Claim 8 (previously presented): The system of claim 1 further comprising:

the coated stent including at least one therapeutic coating disposed on a longitudinal mid-portion of the stent.

Claim 9 (previously presented): The system of claim 8 further comprising:

at least one timing coating disposed on the longitudinal mid-portion of the stent.

Claim 10 (previously presented): The system of claim 8 wherein the therapeutic coating disposed on the longitudinal mid-portion of the stent releases a therapeutic agent that is different from the therapeutic agents released from the therapeutic coatings disposed on the distal and proximal ends of the stent.

Claim 11 (previously presented): The system of claim 8 wherein the therapeutic coating disposed on the longitudinal mid-portion of the stent displays diffusion characteristics that are different from those of the therapeutic coatings disposed on the distal and proximal ends of the stent.

Claim 12 (previously presented): A coated stent, comprising:

a stent framework;

a plurality of therapeutic coatings disposed on a distal end and a proximal end of the stent framework, each therapeutic coating comprising a biocrodable polymer and a therapeutic agent; and

a timing coatings disposed on the distal and proximal ends of the stent framework, the timing coatings alternating with the therapeutic coatings, each timing coating comprising a biocrodable polymer,

wherein a plurality of therapeutic agents is released from the plurality of therapeutic coatings, the therapeutic agents in each of the plurality of therapeutic coatings being

released exclusively and sequentially without release of the therapeutic agents from other of the therapeutic coatings to inhibit restenosis adjacent to the ends of the stent.

Claim 13 (cancelled)

Claim 14 (original): The coated stent of claim 12 wherein the therapeutic agents are selected from a group consisting of an antiproliferative agent, an antineoplastic agent, an antibiotic agent, an anti-inflammatory agent, a free radical scavenger, a protein, and combinations thereof.

Claim 15 (original): The coated stent of claim 12 wherein the therapeutic agents are selected from a group consisting of paclitaxel, dexamethasone, rapamycin, a rapamycin analog, a nonsteroidal anti-inflammatory drug, a steroidal anti-inflammatory drug, a superoxide dismutase mimic, apo A-1 Milano, and combinations thereof.

Claims 16-17 (cancelled)

Claim 18 (previously presented): The coated stent of claim 12 wherein each timing coating prevents release of the therapeutic agent from the therapeutic coating positioned beneath the timing coating until a predetermined time.

Claim 19 (previously presented): The coated stent of claim 12 further comprising:

at least one therapeutic coating disposed on a longitudinal mid-portion of the stent framework.

Claim 20 (previously presented): The coated stent of claim 19 further comprising:

at least one timing coating disposed on the longitudinal mid-portion of the stent framework.

Claim 21 (previously presented): The coated stent of claim 19 wherein the therapeutic coating disposed on the longitudinal mid-portion of the stent releases a therapeutic agent that is different from the therapeutic agents released from the therapeutic coatings disposed on the distal and proximal ends of the stent.

Claim 22 (previously presented): The coated stent of claim 19 wherein the therapeutic coating disposed on the longitudinal mid-portion of the stent displays diffusion characteristics that are different from those of the therapeutic coatings disposed on the distal and proximal ends of the stent framework.

Claim 23 (previously presented): A method of inhibiting restenosis adjacent to the ends of a stent used to treat a vascular condition, comprising:

providing a coated stent, the coated stent including a first and a second therapeutic coating disposed on a distal and a proximal end of the stent, the first therapeutic coating including a bioerodable polymer and a first therapeutic agent, the second therapeutic coating including a second therapeutic agent, the coated stent further including a first timing coating positioned between the first and second therapeutic coatings, the timing coating comprising a bioerodable polymer;

deploying the coated stent in a vessel;

releasing the first therapeutic agent from the first therapeutic coating without releasing the second therapeutic agent from the second therapeutic coating;

eroding the bioerodable polymer of the first therapeutic coating;

actuating the first timing coating based on the eroding of the bioerodable polymer; and

releasing the second therapeutic agent from the second therapeutic coating at a time controlled by the first timing coating.

Claim 24 (original): The method of claim 23 wherein the therapeutic agents are selected from a group consisting of an antiproliferative agent, an antineoplastic agent, an

antibiotic agent, an anti-inflammatory agent, a free radical scavenger, a protein, and combinations thereof.

Claim 25 (original): The method of claim 23 wherein the therapeutic agents are selected from a group consisting of paclitaxel, dexamethasone, rapamycin, a rapamycin analog, a nonsteroidal anti-inflammatory drug, a steroidal anti-inflammatory drug, a superoxide dismutase mimic, apo A-1 Milano, and combinations thereof.

Claim 26 (previously presented): The method of claim 23 further comprising:

releasing a third therapeutic agent from a third therapeutic coating, the third therapeutic agent disposed on a longitudinal mid-portion of the stent framework.

Claim 27 (previously presented): The method of claim 26 further comprising:

first actuating a second timing coating, the second timing coating disposed over the third therapeutic agent on the longitudinal mid-portion of the stent framework.

Claim 28 (original): The method of claim 23 wherein the second therapeutic agent is different from the first therapeutic agent.

Claim 29 (original): The method of claim 26 wherein the third therapeutic agent is different from the first and second therapeutic agents.

Claim 30 (previously presented): The system of claim 1 wherein each of the plurality of therapeutic agents is released from the plurality of therapeutic coatings after the adjacent overlying timing coating has completely eroded.

Claim 31 (previously presented): The coated stent of claim 12 wherein each of the plurality of therapeutic agents is released from the plurality of therapeutic coatings after the adjacent overlying timing coating has completely eroded.

Claim 32 (previously presented): The method of claim 23 wherein the releasing the second therapeutic agent from the second therapeutic coating comprises releasing the second therapeutic agent from the second therapeutic coating after the first timing coating has completely eroded.